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Abstract 
Aim: We sought to determine whether the optimal dual antiplatelet therapy (DAPT) duration after 
drug-eluting stent (DES) placement varies according to clinical presentation.  
Methods and Results: We performed an individual patient data pairwise and network meta-
analysis comparing short-term (≤6-months) versus long-term (1-year) DAPT as well as 3-month vs. 
6-month vs 1-year DAPT. The primary study outcome was the 1-year composite risk of myocardial 
infarction (MI) or definite/probable stent thrombosis (ST). Six trials were included in which DAPT 
after DES consisted of aspirin and clopidogrel. Among 11,473 randomized patients 6,714 (58.5%) 
had stable CAD and 4,758 (41.5%) presented with acute coronary syndrome (ACS), the majority of 
whom (67.0%) had unstable angina. In ACS patients, ≤6-month DAPT was associated with non-
significantly higher 1-year rates of MI or ST compared with 1-year DAPT (HR 1.48, 95%CI 0.98-
2.22; p=0.059), whereas in stable patients rates of MI and ST were similar between the two DAPT 
strategies (HR 0.93, 95%CI 0.65-1.35; p=0.71; Pinteraction=0.09). By network meta-analysis, 3-month 
DAPT, but not 6-month DAPT, was associated with higher rates of MI or ST in ACS, whereas no 
significant differences were apparent in stable patients. Short DAPT was associated with lower 
rates of major bleeding compared with 1-year DAPT, irrespective of clinical presentation. All-cause 
mortality was not significantly different with short vs. long DAPT in both patients with stable CAD 
and ACS. 
Conclusions. Optimal DAPT duration after DES differs according to clinical presentation. In the 
present meta-analysis, despite the fact that most enrolled ACS patients were relatively low risk, 3-
month DAPT was associated with increased ischemic risk, whereas 3-month DAPT appeared safe 
in stable CAD. Prolonged DAPT increases bleeding regardless of clinical presentation. Further 
study is required to identify the optimal duration of DAPT after DES in individual patients based on 
their relative ischemic and bleeding risks.   
Key words: drug-eluting stent, dual antiplatelet therapy, stent thrombosis. 
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Introduction 
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is standard 
therapy in patients with acute coronary syndromes (ACS) and in those undergoing drug-eluting 
stent (DES) implantation, although the obligate duration of DAPT continues to be debated.1 In this 
regard, the extent to which the net benefit of different DAPT durations may vary according to 
clinical presentation is still controversial. Patients with ACS have increased rates of recurrent 
ischemic events compared to those with stable coronary artery disease (CAD),2 and therefore ACS 
patients may be more likely to benefit from prolonged DAPT. However, data on optimal DAPT 
duration are relatively scant and controversial even in ACS patients, warranting further 
investigation.1 As many studies have challenged the notion that 1-year DAPT is necessary after 
DES placement, we performed an individual patient data (IPD) meta-analysis of RCTs investigating 
the safety and efficacy of shortening DAPT to <1 year after DES implantation in patients with and 
without ACS.   
 
Methods 
Study design and selection. For this meta-analysis, we included RCTs enrolling patients 
with stable CAD or ACS undergoing DES implantation and randomized to a short duration of 
DAPT (3-6 months) versus a longer duration (≥1 year), censoring data at 1 year. RCTs comparing 
1-year vs. >1-year DAPT, or enrolling patients not treated with DES were excluded. These criteria 
were applied at the study level.Relevant RCTs were searched in August 2015 through MEDLINE, 
the Cochrane database, the EMBASE database, www.tctmd.com, www.clinicaltrials.gov, 
www.clinicaltrialresults.org, www.cardiosource.com, and abstracts and presentations from major 
cardiovascular meetings, using the keywords randomized clinical trial, drug-eluting stent, dual 
antiplatelet therapy, clopidogrel, aspirin, thienopyridines. Two investigators (TP and DDR) 
independently reviewed the titles, abstracts and studies to determine whether they met the inclusion 
criteria. Risk of bias was assessed using the Cochrane method. Further methodological details of the 
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meta-analysis are provided in the Supplemental Material. The study was performed in compliance 
with the PRISMA IPD statement.3 
Endpoints and definitions. The primary objective was to investigate whether there is an 
interaction between DAPT duration and clinical presentation for the composite risk of 1-year 
myocardial infarction (MI) or definite/probable stent thrombosis (ST). Secondary pre-specified 
endpoints included the 1-year rates of all-cause, cardiac and non-cardiac death, MI, ST, stroke, 
target vessel revascularization (TVR), major bleeding, any bleeding, and various combinations of 
these endpoints. The endpoint definitions as applied in each trial were incorporated. Patient-level 
data were obtained from the principal investigators of the trials meeting the inclusion criteria and 
combined in a single pooled database. Interaction analyses between DAPT duration and clinical 
presentation were performed using frequentist IPD pairwise meta-analysis. Network meta-analysis 
was performed to compare outcomes of 3-month vs. 6-month vs 1-year DAPT separately in ACS 
and non-ACS patients. 
To minimize bias by including events in the early period, landmark analyses were performed 
at the time of DAPT discontinuation in the short-DAPT treatment group. For this analysis, patients 
with ischemic or bleeding events occurring before the landmark time-point, or those not compliant 
with the original randomization assignment were excluded, resulting in a “per-protocol” population.  
Statistical analysis. Continuous variables are displayed as means and standard deviation 
(SD) and were compared using 2-way ANOVA stratified by trial. Categorical variables are 
displayed as counts and percentages and were compared with a logistic regression analysis stratified 
by trial. IPD meta-analysis was performed using a one-stage approach. Patient data were combined 
in a single dataset and fitted in a Cox regression model stratified by trial. The proportional 
assumptions were verified using Schoenfeld residuals. Results are reported as hazard ratio (HR) 
with 95% confidence interval (CI). A simple Cox regression model was used to generate 
cumulative hazard function curves of events for each outcome of interest. Kaplan-Meier estimates 
were also determined. As sensitivity analyses, we investigated the relative risk and benefit of short 
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DAPT versus prolonged DAPT using standard parametric survival models, as well as Royston 
Parmar models.4 For Royston-Parmar models we evaluated 1, 2 and 3 knots of the spline function. 
For the network meta-analysis treatment effect estimates for short vs. long DAPT were 
obtained as log HR and standard error from individual RCTs.5 These estimates were then used to 
obtain head-to-head comparison estimates between different DAPT regimens (3-months vs 6-
months vs 1-year). A frequentist framework based on graph-theoretical method was used to 
calculate point estimates with 95% CI using a random-effects model (R netmeta package).6 Pair-
wise inconsistency was assessed with the I2 statistic. P values <0.05 were considered significant. 
Statistical analyses were performed using Stata 12 SE (StataCorp, College Station, Texas) and R 
3.2.3 (R Foundation for Statistical Computing, Vienna, Austria).  
 
Results 
As shown in Supplemental Figure 1, of 1,042 potentially relevant studies, 7 trials met the 
inclusion criteria. Data were obtained for 6 of them and were included in the final meta-analysis.7-12 
The major characteristics of the included trials are shown in Supplemental Table 1, the inclusion 
and exclusion criteria are reported in Supplemental Table 2, the risk of bias in Supplemental Table 
3, the definitions of clinical endpoints in Supplemental Table 4, and the clinical angiographic and 
procedural characteristics stratified by DAPT duration in Supplemental Table 5. Among 11,473 
randomized patients 4,758 (41.5%) presented with ACS and 6,714 (58.5%) had stable CAD. In 1 
patient the clinical presentation was not defined. The majority of ACS patients (67.0%) had 
biomarker-negative unstable angina. Baseline characteristics of patients with and without ACS 
stratified by different DAPT durations are reported in Supplemental Tables 6-8.  
Clinical outcomes in the intention-to-treat population. At 1-year follow up, patients with 
ACS compared to stable CAD had significantly higher composite rates of MI or definite/probable 
ST (HR=1.50, 95%CI 1.12-2.00; p=0.006), and cardiac death, MI, or definite/probable ST, but 
similar rates of major bleeding. 
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In the entire study population ≤6-month DAPT was associated with similar rates of 
composite MI or definite/probable ST compared to 1-year DAPT (HR 1.15, 95%CI 0.88-1.51; 
p=0.31) with a borderline interaction between DAPT duration and clinical presentation 
(Pinteraction=0.09) (Table 1, Figure 1). Specifically there were 57 MI or ST events among 2,383 ACS 
patients treated with short DAPT and 39 such events among 2,375 ACS patients treated with 1-year 
DAPT (HR 1.48, 95%CI 0.98-2.22; p=0.059). Conversely, there were 55 MI or ST events among 
3,347 patients with stable CAD treated with short DAPT and 59 such events among 3,367 stable 
patients treated with 1-year DAPT (HR 0.93, 95%CI 0.65-1.35; p=0.72).  
≤6-month DAPT duration was associated with lower 1-year rates of major bleeding (HR 
0.50, 95%CI 0.30-0.83; p=0.008) and any bleeding (HR 0.67, 95%CI 0.49-0.91, p=0.01) compared 
with prolonged DAPT, with no interaction between DAPT duration and clinical presentation 
(Figure 1). Additional clinical outcomes and their hazard function curves are shown in Table 1 and 
Figure 2. Of note, all-cause mortality was not significantly different with short vs. long DAPT in 
both patients with stable CAD and ACS. Similar results were apparent in sensitivity analyses using 
parametric survival models as well as Royston Parmar models (Supplemental Tables 9). 
Landmark analysis in the per-protocol population. The per protocol population included 
11,070 patients, including 4,567 (41.3%) with ACS and 6,502 (58.7%) with stable CAD. Their 
baseline characteristics stratified by DAPT duration are presented in Supplemental Tables 10-12. 
For the entire randomized per-protocol population beginning after the time-point of DAPT 
discontinuation, short DAPT was associated with similar rates of composite MI or ST as prolonged 
DAPT (HR 1.02, 95%CI 0.67-1.56, p=0.77), with a borderline interaction favoring prolonged 
DAPT in ACS but not stable CAD (Pinteraction=0.07) (Supplemental Table 13 and Figure 3). 
Significant interactions between DAPT duration and clinical presentation were present for MI and 
TVR, with prolonged DAPT favored in ACS patients and shorter DAPT favored in stable CAD 
patients. Conversely, ≤6-month DAPT was associated with lower 1-year rates of major bleeding 
(HR 0.32, 95%CI 0.14-0.70; p=0.005) and any bleeding (HR 0.48, 95%CI 0.30-0.79, p=0.004) 
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compared with prolonged DAPT, with no interaction between DAPT duration and clinical 
presentation (Supplemental Table 13). Finally, patients treated with short vs. long DAPT had a 
trend toward lower rates of non-cardiac mortality (HR 0.62, 95%CI 0.38-1.01; p=0.058), with a 
non-significant interaction between DAPT duration and clinical presentation (Pinteraction=0.08).  
3-months vs. 6-months vs. 12-months of DAPT. The evidence network is shown in 
Supplemental Figure 2 and the results in Figure 4. All trials included in the meta-analysis were 
sufficiently similar in all respects other than the treatment assignment, holding the transitivity 
assumption of network meta-analysis. Compared with ACS patients treated with 12-month DAPT, 
those treated with 3-month DAPT (HR 2.08, 95%CI 1.10-3.93) but not 6-month DAPT (HR 1.28, 
95%CI 0.73-2.27) had higher composite MI or ST rates. Conversely, there was no significant 
difference in the risk of MI or ST in stable patients treated with 3-month, 6-month, or 12-month 
DAPT. Finally, treatment with 3-month and 6-month DAPT was associated with lower rates of 
major bleeding and any bleeding compared with 12-month DAPT, independent of clinical 
presentation. 
Additional analyses. A significant interaction was apparent between DAPT duration, 
clinical presentation and history of prior MI, such that 1-year DAPT significantly reduced the risk 
of MI or ST compared to short DAPT only in patients with ACS and a history of prior MI, whereas 
no significant difference between the two DAPT strategies was apparent in the other clinical strata 
(Supplemental Table 14). No statistical heterogeneity was present in any pair-wise analyses for the 
main outcome measures (Supplemental Table 15).   
 
Discussion  
The principal findings of the present patient-level pooled meta-analysis including 6 RCTs 
and 11,473 patients are: 1) Overall, a strategy of short-term DAPT (3 or 6 months) after DES 
implantation is associated with  similar 1-year composite rates of MI or definite/probable ST 
compared with 1-year DAPT, with a borderline interaction between DAPT duration and clinical 
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presentation; 2) Similar results were seen in the per-protocol population in the landmark period 
between DAPT discontinuation and 1-year follow-up; 3) In patients with ACS, 3-month but not 6-
month DAPT was associated with higher rates of MI or ST compared with 1-year DAPT, whereas 
in stable CAD no such difference was apparent; 4) Patients with both ACS and stable CAD treated 
with short DAPT (either 3 or 6 months) had lower rates of bleeding compared to patients treated 
with 1-year DAPT; and 5) Although by intention-to-treat all-cause mortality was not significantly 
different with short vs. long DAPT, a trend towards increased non-cardiac mortality with prolonged 
compared with short DAPT was present in the per-protocol landmark period between DAPT 
discontinuation and 1-year follow-up, with no interaction present between DAPT duration and 
clinical presentation in either analysis. 
Several RCTs have recently challenged the notion that 1-year (or longer) DAPT is necessary 
after contemporary DES implantation, suggesting that 6-month or even 3-month DAPT may be as 
effective and safer.7-13 In stable CAD, European and US guidelines state 6-month DAPT may be 
reasonable after second generation DES in stable CAD.14, 15 The optimal DAPT duration in patients 
with ACS is also controversial. There is general consensus that in such patients DAPT should be 
administered for at least1 year, but the evidence supporting this recommendation relies on a single 
randomized trial (CURE) performed nearly 2 decades ago when ACS patients were treated 
conservatively, and before DES.16 In this regard second generation DES may be less thrombogenic 
than bare metal stents.17 In CURE, a reduction in the risk of cardiovascular death, MI or stroke 
favoring DAPT with clopidogrel compared with aspirin monotherapy was already apparent at 30 
days, confounding interpretation of the utility of DAPT thereafter. Unfortunately, a second 
randomization at a later time period was not performed, which might have addressed this issue. 
Moreover, landmark analysis from CURE demonstrated that nearly all of the benefit of DAPT 
occurred within 3 months after randomization.18 Specifically, DAPT compared with aspirin 
monotherapy prevented 20 cardiovascular events/1,000 patients treated during the first 3 months, 
vs. only 2 initial cardiovascular events/1,000 patients treated between 3 and 12 months. In addition, 
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among 2,658 patients undergoing PCI, no significant difference in any ischemic endpoint was 
apparent between aspirin monotherapy versus DAPT in a landmark period between 1 month and 1 
year.19  
In the present patient-level pooled meta-analysis including 11,473 patients, 4,758 of whom 
had ACS, we found no significant difference in the risk of MI or definite/probable stent thrombosis 
between ≤6-month DAPT versus 1-year DAPT in the entire randomized population. However, a 
trend was apparent suggesting a significant benefit of 1-year DAPT vs. shorter DAPT in ACS 
patients, and by network meta-analysis 3-month DAPT, but not 6-month DAPT was associated with 
significantly higher rates of MI or ST in ACS. In contrast, no significant difference in the risk of MI 
or ST was apparent in patients with stable CAD treated with 3, 6 or 12 months DAPT. 
These findings contrast with the DAPT trial, which suggested higher rates of ST and MI in 
patients treated with 1-year DAPT compared with 2.5-year DAPT after DES, irrespective of clinical 
presentation.20, 21 The difference in DAPT duration between treatment arms was 18 months in the 
DAPT trial, but only 6-9 months in our meta-analysis. It is possible that a benefit may appear with 
DAPT continuation longer than 1 year. Moreover, in the DAPT trial, the benefit of prolonged 
DAPT was accentuated in patients with MI at presentation,21 consistent with the results of the 
present study. Our analysis confirms that prolonging DAPT carries a substantial risk of major 
bleeding and any bleeding. These findings are of clinical relevance considering the association 
between bleeding and mortality.22 In addition, a meta-regression analysis including 8 RCTs has 
recently found a significant association between all bleeding and non-cardiovascular mortality, but 
not between ST and cardiovascular mortality, suggesting that these endpoints may weigh differently 
on the risk of mortality.23 In this regard, we observed a borderline increase in non-cardiac mortality 
with prolonged DAPT compared with aspirin monotherapy in the landmark period between DAPT 
discontinuation and 1-year. 
These data suggest that the optimal DAPT duration after DES placement should be tailored 
in individual patients after carefully balancing the risks of ischemic versus bleeding events. The 
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DAPT score was developed to identify patients with a greater risk of ischemia than bleeding who 
may benefit the most from prolonging DAPT.21 Limitations of this score include its modest 
discrimination power, absence of ticagrelor treatment, applicability only to the 12 to 30-month 
period after DES, and lack of availability of several important variables predicting bleeding.22 The 
DAPT score also needs external validation in a trial of different DAPT durations using 
contemporary DES. Further studies are thus warranted to investigate the utility of the DAPT score. 
The majority of enrolled patients with ACS were biomarker negative, and few had acute 
STEMI, representing a relatively low-risk cohort. However, 1-year DAPT significantly reduced the 
risk of MI or ST compared with short DAPT in patients with ACS and prior MI, whereas no 
significant difference were apparent in other clinical strata. These findings are consistent with the 
results of the PEGASUS trial, which showed significantly lower rates of ischemic events with long-
term DAPT with aspirin and ticagrelor compared to aspirin alone in patients with prior MI 1 to 3 
years earlier,24 and with a recent meta-analysis reporting benefit of long-term DAPT for secondary 
prevention in patients with previous MI.25  
Other limitations should be acknowledged. The analysis in patients with prior MI is 
underpowered and therefore should be interpreted with caution. A significant proportion of 
implanted DES were first generation devices, in particular fast-release zotarolimus-eluting stents, 
which are no longer used. However, as second generation DES are safer than first generation 
DES,17 the balance between risk and benefit would likely favor shorter DAPT duration to an even 
greater degree with contemporary DES. Although we observed no significant difference in the risk 
of ischemic events between 3-month versus 1-year DAPT in patients with stable CAD, further 
studies are required to establish the generalizability of this finding. All trials included in the meta-
analysis were open-label, potentially introducing bias. Definitions of some clinical endpoints 
slightly differed across trials, potentially introducing effect modifiers. All patients were treated with 
clopidogrel as adjunctive therapy to aspirin. It remains undetermined how the more potent 
antiplatelet agents prasugrel and ticagrelor might affect the risk-benefit balance of prolonged DAPT 
 11 
 
in ACS. Comparison between 3-month versus 6-month DAPT is based on indirect evidence only, 
and therefore should be interpreted with caution. Data from the large ISAR SAFE trial were not 
provided by the principal investigator, and therefore could not be included in the meta-analysis.13 
The lack of a significant difference in the risk of ischemic endpoints between 6-month and 1-year 
DAPT in ACS patients should be interpreted with caution, given the low risk nature of these 
patients (67.0% unstable angina), and the trend toward greater ischemic events with 6-month 
DAPT. Thus 1-year mandatory DAPT would be a prudent minimum in high-risk ACS patients.  
Considering the small number of studies included in the meta-analysis, we did not use common 
methods for evaluating publication bias such as Egger test or the funnel plot. 
In conclusion, in the present meta-analysis including 11,473 patients treated with DES, the 
absolute and relative benefit of different DAPT durations varied according to clinical presentation. 
In patients with ACS, 3-month DAPT was associated with increased ischemic risk, whereas 3-
month DAPT appeared safe in stable CAD. Prolonged DAPT increases bleeding regarding of 
clinical presentation. Further study is required to identify the optimal duration of DAPT after DES 
in individual patients at varying level of ischemic and bleeding risk.   
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Figure legends 
Figure 1. Main clinical outcomes and interaction analysis between dual antiplatelet therapy 
(DAPT) duration and clinical presentation in the intention-to-treat population. MI, myocardial 
infarction; ST, definite/probable stent thrombosis; CAD, coronary artery disease; ACS, acute 
coronary syndrome; HR, hazard ratio; CI, confidence interval. 
Figure 2. Cumulative hazard function curves determined by Cox regression analyses in the overall 
population and in patients with or without acute coronary syndrome (ACS) showing the 1-year risk 
of (A) myocardial infarction (MI) or definite/probable stent thrombosis (ST); (B) cardiac death, MI 
or ST; (C) major bleeding; and (D) any bleeding with ≤6-month versus 1-year dual antiplatelet 
therapy (DAPT).  
Figure 3. Major clinical outcomes and interaction analysis between dual antiplatelet therapy 
(DAPT) duration and clinical presentation in the per-protocol population in the landmark period 
between DAPT discontinuation and 1 year. Short DAPT indicates 3 or 6-month DAPT. 
Abbreviations as in Figure 1. 
Figure 4. Forest plot illustrating major clinical outcomes with 3-month versus 6-month versus 1-
year DAPT in the entire population and in patients with or without acute coronary syndromes. 
(ACS). Abbreviations as in Figure 1.
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Table 1. Clinical outcomes and interaction analysis of short-term (≤6-month) versus long-
term (1-year) dual antiplatelet therapy in patients stratified by clinical presentation  
 
 
 
Estimated risk of 
short versus long DAPT* 
Hazard ratio 
(95%CI) 
Interaction 
p 
MI or definite/probable 
ST 
  0.09 
All patients 1.98% vs. 1.74% 1.15 (0.88-1.51)  
  - Stable CAD 1.67% vs. 1.79% 0.93 (0.65-1.35)  
  - ACS  2.43% vs. 1.67% 1.48 (0.98-2.22)  
Cardiac death   0.48 
All patients 1.03% vs. 1.19% 0.86 (0.61-1.23)  
  - Stable CAD 1.01% vs. 1.03% 0.97 (0.60-1.57)  
  - ACS  1.07% vs. 1.41% 0.75 (0.45-1.27)  
Non-cardiac death   0.82 
All patients 0.70% vs. 0.74% 0.95 (0.61-1.47)  
  - Stable CAD 0.52% vs. 0.58% 0.89 (0.47-1.72)  
  - ACS  0.95% vs. 0.97% 0.99 (0.55-1.80)  
All-cause death   0.77 
All patients 1.71% vs. 1.92% 0.89 (0.67-1.17)  
  - Stable CAD 1.49% vs. 1.60% 0.92 (0.63-1.36)  
  - ACS  2.02% vs. 2.37% 0.85 (0.58-1.26)  
MI   0.14 
All patients 1.79% vs. 1.63% 1.10 (0.83-1.47)  
  - Stable CAD 1.51% vs. 1.66% 0.91 (0.62-1.34)  
  - ACS  2.17% vs. 1.18% 1.39 (0.91-2.13)  
Stroke   0.11 
All patients 0.46% vs. 0.50% 0.92 (0.55-1.59)  
  - Stable CAD 0.34% vs. 0.55% 0.61 (0.29-1.30)  
  - ACS  0.64% vs. 0.43% 1.49 (0.67-3.33)  
Definite/probable ST   0.27 
All patients 0.49% vs. 0.42% 1.17 (0.68-2.02)  
  - Stable CAD 0.36% vs. 0.42% 0.86 (0.40-1.86)  
  - ACS  0.68% vs. 0.43% 1.59 (0.72-3.51)  
Any bleeding   0.11 
All patients 1.19% vs. 1.78% 0.67 (0.49-0.91)  
  - Stable CAD 1.51% vs. 1.91% 0.79 (0.55-1.14)  
  - ACS  0.73% vs. 1.60% 0.45 (0.26-0.81)  
Major bleeding   0.84 
All patients 0.39% vs. 0.78% 0.50 (0.30-0.83)  
  - Stable CAD 0.42% vs. 0.82% 0.52 (0.27-0.99)  
  - ACS  0.34% vs. 0.73% 0.47 (0.20-1.08)  
Target vessel 
revascularization 
  0.07 
All patients 3.36% vs. 2.97% 1.14 (0.92-1.41)  
  - Stable CAD 2.91% vs. 3.07% 0.96 (0.72-1.27)  
  - ACS  3.98% vs. 2.83% 1.42 (1.04-1.95)  
Cardiac death, MI, or 
definite/probable ST 
  0.34 
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All patients 2.74% vs. 2.55% 1.08 (0.86-1.36)  
  - Stable CAD 2.42% vs. 2.48% 0.97 (0.72-1.33)  
  - ACS  3.20% vs. 2.65% 1.22 (0.87-1.71)  
Cardiac death or MI   0.55 
All patients 2.64% vs. 2.48% 1.07 (0.85-1.35)  
  - Stable CAD 2.36% vs. 2.36% 1.00 (0.73-1.37)  
  - ACS  3.03% vs. 2.65% 1.16 (0.82-1.63)  
Cardiac death, MI, or 
stroke 
  0.35 
All patients 2.92% vs. 2.82% 1.04 (0.84-1.30)  
  - Stable CAD 2.61% vs. 2.76% 0.95 (0.71-1.27)  
  - ACS  3.37% vs. 2.91% 1.17 (0.85-1.62)  
Cardiac death, MI, stroke, 
or major bleeding 
  0.33 
All patients 3.38% vs. 3.50% 0.97 (0.79-1.18)  
  - Stable CAD 3.06% vs. 3.44% 0.88 (0.68-1.16)  
  - ACS  3.84% vs. 3.59% 1.08 (0.80-1.45)  
All-cause death or MI   0.72 
All patients 2.65% vs. 2.69% 0.99 (0.79-1.24)  
  - Stable CAD 2.31% vs. 2.24% 1.03 (0.75-1.42)  
  - ACS  3.13% vs. 3.32% 0.94 (0.69-1.31)  
All-cause death, MI, or 
stroke 
  0.73 
All patients 2.93% vs. 2.97% 0.99 (0.80-1.23)  
  - Stable CAD 2.53% vs. 2.46% 1.03 (0.76-1.40)  
  - ACS  3.51% vs. 3.71% 0.95 (0.71-1.29)  
All-cause death, MI, 
stroke,  or major bleeding 
  0.73 
All patients 3.13% vs. 3.39% 0.93 (0.76-1.14)  
  - Stable CAD 2.74% vs. 2.85% 0.96 (0.72-1.28)  
  - ACS  3.69% vs. 4.14% 0.89 (0.67-1.29)  
CAD, coronary artery disease; DAPT, dual antiplatelet therapy; ACS, acute coronary MI, 
myocardial infarction; ST, stent thrombosis, HR, hazard ratio; CI, confidence interval. *Determined 
by Kaplan-Meier analysis. 
 
 
 
 
 
